‘Medicare for all’ would cost $32.6T over 10 years

Considering healthcare will be a central topic in the run up to the 2018 mid-term elections, “Medicare for all” is a concept that is gaining traction among left-leaning politicians. A recent study, though, found that implementation of such a program would cost $32.6 trillion over 10 years.

Mercatus Center at George Mason University in Virginia, a libertarian policy center subsidized by the billionaire conservative activists Charles and David Koch, reported such a policy would require historic tax hikes, according to the AP.

“Enacting something like ‘Medicare for all’ would be a transformative change in the size of the federal government,” said study author Charles Blahous, who was an economic adviser to George W. Bush and a public trustee of Social Security and Medicare during the Obama administration.

While the study cited an increase of $32.6 trillion over 10 years, some economists noted federal healthcare spending would drop overall by just more than $2 trillion.

All U.S. residents would be covered by the proposed health-care policy without copays or deductibles. “Medicare for all” was a central tenet to the 2016 presidential bid of Bernie Sanders, I-Vermont. The democratic socialist released a video thanking the study researchers for showing the plan could produce major savings.

"Let me thank the Koch brothers, of all people, for sponsoring a study that shows that Medicare for All would save the American people $2 trillion over a 10-year period," Sanders said. "I suspected that is not what the Koch brothers intended to do, but that is what is in the study."

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.